Multi-Strain OEM/ODM Supplements: Blend Sampling & Enumeration

Decide what the blend specification must show

A multi-strain formula can require several different answers: whether the intended strains are present, whether total viable count is acceptable, and whether composition remains as intended. List these questions individually. A laboratory report headed probiotic count should not be assumed to resolve all three.

Connect the testing questions to the proposed formula and label description. If the product differentiates individual strains, discuss what evidence supports that differentiation. Avoid setting a specification that the laboratory cannot meaningfully verify once closely related organisms have been combined.

Understand the method before ordering the blend

Plate counting on a nonselective medium measures colonies under those conditions; it does not automatically assign them to each strain. A recent proof-of-concept study combined plate counts with an identification technique to address selective enumeration. It illustrates a method challenge rather than validating every commercial consortium.

Give the laboratory the actual strains and anticipated proportions. Ask about selectivity, recovery, and interference from the carrier. If identity testing uses molecular methods, clarify whether and how that method distinguishes viable organisms. Separate the laboratory capabilities from the claims made on a supplier brochure.

Prepare samples that represent the process

Plan sampling at locations relevant to blending, transfer, and filling. A culture preparation can differ physically from another component, so a well-mixed appearance alone cannot demonstrate distribution. Define the number and location of samples using the scale and operation being evaluated.

Avoid combining all development samples into one composite if the purpose is to investigate serving variability. A composite may hide differences between positions. Discuss which samples remain separate, which may be pooled, and what result would trigger an investigation or another process trial.

Keep preparation and laboratory histories connected

Record the blend revision, original culture lots, sample collection time, shipping conditions, and analysis timing. Include the amount of each supplied preparation added. Without that record, a low result may be difficult to distinguish from a material issue, a process loss, or an inappropriate sample shipment.

Agree on the handling of discordant results before commercial release. Repeating a test without a defined investigation can produce numbers without an explanation. Preserve original observations and document any reason for changing sample preparation, enumeration conditions, or the intended acceptance criteria.

Follow composition through packaged storage

Different strains may not behave identically during storage. Consider whether the stability program needs more information than a total count. The study should answer the product specification rather than simply use whichever aggregate result is least expensive to obtain.

When the blend supplier changes one strain, review method selectivity and the sampling rationale again. A method that separated the original consortium may not distinguish the revised one. Approve the new evidence together with the formula so the testing program continues to describe the product actually manufactured.

Explore relevant dosage forms

Compare manufacturing considerations for your intended product. Suitability depends on the complete formulation.

Common questions